The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.

The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows ...

Moderna has announced FDA approval for its new COVID-19 vaccine, mNexspike (mRNA-1283). This next-generation shot targets a ...

The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...

The World Health Organization has tracked a new COVID-19 variant that has emerged across multiple region. Amid this, the Food ...

Approval was based on data from the Phase III NextCOVE trial, which demonstrated that mNEXSPIKE met non-inferiority criteria ...